CN118843466A - 治疗小细胞肺癌的方法 - Google Patents

治疗小细胞肺癌的方法 Download PDF

Info

Publication number
CN118843466A
CN118843466A CN202380026002.5A CN202380026002A CN118843466A CN 118843466 A CN118843466 A CN 118843466A CN 202380026002 A CN202380026002 A CN 202380026002A CN 118843466 A CN118843466 A CN 118843466A
Authority
CN
China
Prior art keywords
administered
wee1 inhibitor
etoposide
day
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380026002.5A
Other languages
English (en)
Chinese (zh)
Inventor
埃斯特万·罗德里戈伊梅迪奥
卢克·皮戈特
安妮·贝隆
瓦莱丽·尼古拉斯
安妮·瓦斯林切塞克斯
拉尔斯·达姆斯特鲁普
克劳迪奥·赞娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Debiopharm International SA
Original Assignee
Debiopharm International SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm International SA filed Critical Debiopharm International SA
Publication of CN118843466A publication Critical patent/CN118843466A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380026002.5A 2022-03-07 2023-03-07 治疗小细胞肺癌的方法 Pending CN118843466A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22160556 2022-03-07
EP22160556.1 2022-03-07
PCT/EP2023/055751 WO2023170065A1 (en) 2022-03-07 2023-03-07 Methods of treating small cell lung cancer

Publications (1)

Publication Number Publication Date
CN118843466A true CN118843466A (zh) 2024-10-25

Family

ID=80682926

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380026002.5A Pending CN118843466A (zh) 2022-03-07 2023-03-07 治疗小细胞肺癌的方法

Country Status (12)

Country Link
US (1) US20260027117A1 (https=)
EP (1) EP4489756A1 (https=)
JP (1) JP2025509278A (https=)
KR (1) KR20240158972A (https=)
CN (1) CN118843466A (https=)
AR (1) AR128711A1 (https=)
AU (1) AU2023232376A1 (https=)
CA (1) CA3253688A1 (https=)
IL (1) IL315441A (https=)
MX (1) MX2024010900A (https=)
TW (1) TW202337469A (https=)
WO (1) WO2023170065A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025186213A1 (en) * 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor
CN118581045A (zh) * 2024-07-29 2024-09-03 云南省肿瘤医院(昆明医科大学第三附属医院) 一株多突变的人小细胞肺癌淋巴结转移原代细胞系及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2608940T3 (es) 2007-06-15 2017-04-17 Msd K.K. Derivado de bicicloanilina
CN104271576A (zh) 2012-02-23 2015-01-07 艾伯维公司 激酶的吡啶并嘧啶酮抑制剂
US10703759B2 (en) 2016-11-16 2020-07-07 Impact Therapeutics, Inc 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
WO2022155202A1 (en) 2021-01-13 2022-07-21 Schrödinger, Inc. Fused heterocycles and uses of same
WO2022188802A1 (en) * 2021-03-10 2022-09-15 Impact Therapeutics (Shanghai) , Inc Use of wee1 kinase inhibitors in the treatment of cancer
AU2022287033B2 (en) 2021-06-04 2025-04-17 Aprea Therapeutics, Inc. Pyridopyrimidine derivatives useful as wee1 kinase inhibitors
WO2023093840A1 (en) * 2021-11-26 2023-06-01 Impact Therapeutics (Shanghai) , Inc Use of wee1 kinase inhibitors in the treatment of cancer

Also Published As

Publication number Publication date
AR128711A1 (es) 2024-06-05
US20260027117A1 (en) 2026-01-29
AU2023232376A1 (en) 2024-10-10
KR20240158972A (ko) 2024-11-05
MX2024010900A (es) 2024-09-17
WO2023170065A1 (en) 2023-09-14
JP2025509278A (ja) 2025-04-11
CA3253688A1 (en) 2023-09-14
IL315441A (en) 2024-11-01
TW202337469A (zh) 2023-10-01
EP4489756A1 (en) 2025-01-15

Similar Documents

Publication Publication Date Title
US20240226090A1 (en) Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
JP6805336B2 (ja) 薬学的組み合わせ
EP2892535B1 (en) Method of adjuvant cancer treatment
CN118843466A (zh) 治疗小细胞肺癌的方法
TW202329946A (zh) 用於治療癌症之方法及包含cdk2抑制劑之給藥方案
US20220241294A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
JP2024511836A (ja) 膵臓癌の治療のためのｐｉ３ｋ－デルタ阻害剤
EP2663318B1 (en) Pharmaceutical composition for treating cancer
CN120676946A (zh) Debio-0123与替莫唑胺和放射治疗组合用于治疗胶质瘤
US12447147B2 (en) Methods of treating, ameliorating, and/or preventing cancer using pyrvinium compositions
CN114533886B (zh) 一种用于晚期乳腺癌治疗的药物组合物
AU2024343230A1 (en) Combination of a wee1 inhibitor and a pkmyt1 inhibitor
HK40070843A (en) Dabrafenib and trametinib in a method of adjuvant cancer treatment
JP2024500628A (ja) 腫瘍治療のための４－アミノ－ｎ－［４－（メトキシメチル）フェニル］－７－（１－メチルシクロプロピル）－６－（３－モルホリノプロパ－１－イン－１－イル）－７ｈ－ピロロ［２，３－ｄ］ピリミジン－５－カルボキサミドの使用法
HK1248608B (en) Combinations of liposomal irinotecan, 5-fu and leucovorin for the treatment of pancreatic cancer
HK1206642B (en) Method of adjuvant cancer treatment
HK1209627B (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination